COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) (TEMPEST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00041509
Recruitment Status : Completed
First Posted : July 12, 2002
Last Update Posted : May 30, 2017
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to gain additional safety information as well as to determine after the study drug has been given to patients who have undergone total hip replacement surgery, whether the study drug is effective in preventing late deep vein thrombosis (blood clots in legs) or pulmonary embolism (blood clots in lungs).

Condition or disease Intervention/treatment Phase
Arthroplasty Drug: SB-424323 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 343 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty
Study Start Date : January 2002
Actual Primary Completion Date : May 2003
Actual Study Completion Date : May 2003

Arm Intervention/treatment
Experimental: SB424323, 500 mg BID Drug: SB-424323
500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days

Experimental: SB424323, 125 mg BID Drug: SB-424323
500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days

Placebo Comparator: Placebo Drug: Placebo
matching placebo, oral, BID for 28 days

Primary Outcome Measures :
  1. VTE [ Time Frame: 28 day treatment period ]
    Incidence of VTE during the 28-day treatment period, including death due to VTE

Secondary Outcome Measures :
  1. types of VTE [ Time Frame: 28 day treatment period ]
    The incidence of the types of VTE including, DVT (deep vein thrombosis), symptomatic VTE, PE] and anti-IIa activity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients scheduled for primary elective unilateral total hip arthroplasty (i.e. first time the hip is being replaced on the operative side).
  • Patients who have given written informed consent to participate in this study.

Exclusion Criteria:

  • Patients with a contraindication to contrast venography
  • Patients with an increased risk of bleeding.
  • Patients with a predefined risk for prethrombotic episodes or a history of thrombophilia.
  • Other inclusion or exclusion criteria to be determined by the physician and study sponsor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00041509

Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT00041509    
Other Study ID Numbers: 424323/025
First Posted: July 12, 2002    Key Record Dates
Last Update Posted: May 30, 2017
Last Verified: May 2017
Keywords provided by GlaxoSmithKline:
venous thromboembolism
pulmonary embolism
deep vein thrombosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases